WHAT: The Center for Advancing Innovation (CAI), the Avon Foundation for Women, and National Cancer Institute (NCI), part of the National Institutes of Health, will announce 10 business plan winners and finalists for the first Breast Cancer Startup Challenge. Each winning team will receive a $5,000 award from the Avon Foundation for Women and CAI.
WHEN: March 5, 2014 from 1 to 3 p.m. EST. Media availability is limited before, during and after event. Interviews with awardees and other speakers can be arranged upon request. The event can be viewed via a live webcast at www.videocast.nih.gov.
WHERE: National Cancer Institute, Shady Grove Campus, 9609 Medical Center Drive, Room: TE406 (terrace level of East wing), Rockville, Md. 20850
WHY: The Breast Cancer Start-up Challenge provides teams of business, legal, medical/scientific, engineering, and computer science students, as well as seasoned entrepreneurs, the opportunity to create strategic business plans and start new companies focused on developing and commercializing 10 inventions that could show benefit in breast cancer and potentially other diseases.
WHO: National Cancer Institute: Douglas Lowy, M.D., deputy director
Avon Foundation for Women: Marc Hurlbert, Executive Director
NCI Inventors: Tom Misteli, head, Cell Biology of Genomes Group; Mitchell Ho, head, Antibody Therapy Section Investigator; others
The Center for Advancing Innovation: Rosemarie Truman, Founder, CEO
Winners: (up to 10 awardees)
Examples of three inventions for business consideration in the Challenge include:
Pairing patients with optimal breast cancer treatment: Approximately one in eight women will be diagnosed with breast cancer in their lifetime. The Challenge invention will potentially be used to identify specific therapies that patients will be most responsive to, saving the patient from undergoing unnecessary and costly treatments.
New treatment for triple-negative breast cancer subtype: 63,000 women are diagnosed with late stage triple-negative disease annually and 70 percent of those women will die within 5 years. The Challenge invention will potentially be used to develop a new class of therapeutics using a naturally occurring aspect of the person's immune system, thereby allowing the body to naturally respond to the cancer.
Biodegradable breast reconstruction and cancer recurrence prevention: Up to 20 percent of women who have a breast cancer removed surgically will see the cancer recur. The Challenge invention could be applied to reconstructing the breast with a three dimensional, biodegradable platform with anti-tumor properties that is injected directly after breast tissue removal. This new process will hopefully eliminate the need for invasive cosmetic surgery and reduce cancer recurrence.